BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M. Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. Front Psychiatry 2021;12:623684. [PMID: 33679481 DOI: 10.3389/fpsyt.2021.623684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Onyameh EK, Ofori E, Bricker BA, Gonela UM, Eyunni SVK, Kang HJ, Voshavar C, Ablordeppey SY. Design and discovery of a high affinity, selective and β-arrestin biased 5-HT7 receptor agonist. Med Chem Res 2022;31:274-83. [DOI: 10.1007/s00044-021-02797-4] [Reference Citation Analysis]
2 Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J. Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases. Eur J Med Chem 2022;227:113931. [PMID: 34710746 DOI: 10.1016/j.ejmech.2021.113931] [Reference Citation Analysis]
3 Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. Ther Adv Psychopharmacol 2021;11:20451253211034320. [PMID: 34497709 DOI: 10.1177/20451253211034320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Loebel A, Koblan KS, Tsai J, Deng L, Fava M, Kent J, Hopkins SC. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. J Affect Disord 2022;296:549-58. [PMID: 34614447 DOI: 10.1016/j.jad.2021.09.109] [Reference Citation Analysis]
5 Fukuyama K, Okada M. Effects of an Atypical Antipsychotic, Zotepine, on Astroglial L-Glutamate Release through Hemichannels: Exploring the Mechanism of Mood-Stabilising Antipsychotic Actions and Antipsychotic-Induced Convulsion. Pharmaceuticals (Basel) 2021;14:1116. [PMID: 34832898 DOI: 10.3390/ph14111116] [Reference Citation Analysis]
6 Fukuyama K, Nakano T, Shiroyama T, Okada M. Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions. Int J Mol Sci 2021;22:4122. [PMID: 33923533 DOI: 10.3390/ijms22084122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shiroyama T, Fukuyama K, Okada M. Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43. Int J Mol Sci 2021;22:10013. [PMID: 34576176 DOI: 10.3390/ijms221810013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fukuyama K, Okada M. Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43. Int J Mol Sci 2021;22:5623. [PMID: 34070699 DOI: 10.3390/ijms22115623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ślifirski G, Król M, Turło J. 5-HT Receptors and the Development of New Antidepressants. Int J Mol Sci 2021;22:9015. [PMID: 34445721 DOI: 10.3390/ijms22169015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Asada R, Ogushi Y, Hori H, Kawasaki H. Successful treatment for major depressive disorder with psychotic features with addition of asenapine on escitalopram. Psychogeriatrics 2022. [PMID: 35141987 DOI: 10.1111/psyg.12812] [Reference Citation Analysis]